It is time to recognize that the quality, not quantity, of myocardium in hypertensive heart disease is responsible for adverse cardiovascular events. Experimental and clinical available data indicate that myocardial fibrosis due to the exaggerated accumulation of collagen type I and type III fibers predisposes to an enhanced risk of diastolic and/or systolic ventricular dysfunction, symptomatic heart failure, ischemic heart disease, and arrhythmias in patients with hypertensive heart disease. Thus, management of these patients must not only focus on detection and regression of left ventricular hypertrophy. Far more sensible are interventions aimed to detect and target hypertensive myocardial fibrosis. The available data on the use of biochemical and/or imaging methodologies to address excessive accumulation of collagen fibers in the myocardium of hypertensive patients are promising. On the other hand, preliminary data suggest that the goal of reducing myocardial fibrosis is achievable in patients with hypertensive heart disease treated with specific antihypertensive agents. Collectively, these findings set the stage for larger trials where-in noninvasive measures and reparative strategies of myocardial fibrosis to prevent heart failure could prove useful.
THE CARDIAC COLLAGEN NETWORK
By definition, a collagen is a structural protein of the extracellular matrix that contains at least one domain in the characteristic triple helical conformation [1] . The triple helix is formed by three polypeptide chains ( chains). All collagen molecules are characterized by a central collagen domain composed of repeating Gly-Xaa-Yaa triplets, a high contain of proline, alanine, and lysine residues and noncollagenous domains at their terminal ends [2, 3] . To date, 20 different collagen types have been identified [4] . Although several collagen types are transiently expressed during embryonic development and may play important roles in migration, differentiation and organization of the heart, collagens type I and type III are the major fibrillar collagens of the adult heart [5] . The collagen type I/collagen type III ratio for human heart has been reported at 1.3-1.9:1 [6] . In the ventricular myocardium, fibroblasts are responsible for the biosynthesis of collagens type I and type III [7, 8] . In the heart, more than half of the collagen synthesized is degraded intracellularly, with the remaining either deposited or degraded extracellularly by collagenase and other matrix metalloproteinases [9, 10] . Collagenase is produced by fibroblasts, inflammatory cells, as well cardiomyocytes [11, 12] and it is predominantly present in its latent form [13] . As in other organs, collagen turnover of normal adult heart results from the equilibrium between the synthesis and degradation of collagens type I and type III. A number of factors have been described that may alter the balance in favour of either the synthesis or the degradation [14, 15] .
Fibrillar collagen of the heart provides the structural scaffolding for cardiomyocytes and coronary vessels and imparts *Address correspondence to this author at the Área de Ciencias Cardiovasculares, Edifício CIMA, Av. Pío XII, 55, 31008 Pamplona, Spain; Tel: 34-948-194700; Fax: 34-948-194716; E-mail: jadimar@unav.es cardiac tissue with physical properties that include stiffness and resistance to deformation [15, 16] . In addition, fibrillar collagen may also act as a link between contractile element of adjacent cardiomyocytes and as a conduit of information that is necessary for cell function. This is supported by the observation that the interaction of collagen fibers in the heart with cardiomyocytes occurs at regions near the Z band, and the cell attachment is mediated by specific molecules belonging to the family of integrins [17] . Thus, cardiac fibrillar collagen not only determines tensile strength and compliance of the left ventricular chamber, but also integrates individual cardiomyocyte contractions into a coordinated biologic pump for expulsion of blood into the systemic and pulmonary circulations.
PATHOPHYSIOLOGICAL ASPECTS OF MYOCAR-DIAL FIBROSIS IN HYPERTENSIVE HEART DIS-EASE (HHD)
An exaggerated accumulation of collagen type I and type III fibers within the interstitium (i.e., interstitial fibrosis, Fig.  1A ) and surrounding intramural coronary arteries and arterioles (i.e., perivascular fibrosis, Fig. 1B) is one of the key features of structural remodeling of the left ventricle in HHD, here defined as a greater than normal left ventricular mass (i.e., left ventricular hypertrophy or LVH) in the absence of a cause other than arterial hypertension. In fact, various studies performed in human heart post-mortem specimens [18] [19] [20] and endomyocardial human biopsy samples [21] [22] [23] [24] have shown that the portion of myocardial volume occupied by collagen fibers (collagen volume fraction or CVF) is significantly increased in the hearts of patients with HHD compared with that in normotensive people. Fibrosis in HHD is present not only in the left ventricular free wall, but also in the interventricular septum, right ventricular free wall and both atria. The excess of myocardial collagen seen in hypertension is suggested to be the result of both increased collagen synthesis by fibroblasts and myofibroblasts and unchanged or decreased collagen degradation by matrix metalloproteinases [25] . The available data indicate that besides mechanical stress secondary to hemodynamic overload, a variety of cytokines, growth factors and hormones, namely those belonging to the renin-angiotensinaldosterone system (RAAS), might contribute to the predominance of collagen synthesis over degradation in the hypertensive heart [25, 26] . In turn, myocardial fibrosis might contribute to the increased risk of cardiac complications seen in patients with HHD [26] .
Myocardial Fibrosis and Cardiac Dysfunction
A linkage between fibrosis and left-ventricular dysfunction or failure may be established (Fig. 2) . Initially, the accumulation of collagen tissue within the myocardial interstitium causes reduced ventricular compliance during diastole. This change can be attributed to the inherent stiffness of collagen type I which, as measured by Young's modulus of elasticity, is approximately 30-fold higher than that of cardiomyocyte [27] . Increasing chamber stiffness is accompanied by impaired cardiomyocyte relengthening during relaxation. Improper cardiomyocyte relaxation results in aberrant ventricular filling and is associated with increased filling pressures, thus contributing to impaired diastolic function [28] . The continous accumulation in collagen causes alterations to ventricular geometry, resulting in impaired sarcomere extension [29] . As the force of ventricular contraction is directly related to sarcomere length, the fibrosed heart has a greatly reduced ability to produce adequate pressures for systemic perfusion. Thus, systolic dysfunction is also related to the presence of myocardial fibrosis.
These mechanisms are supported by several clinical findings. Ohsato et al. [30] reported that CVF was the most significant factor related to diastolic dysfunction in hypertensives. Brilla et al. [23] reported that diminution of CVF after treatment with lisinopril was accompanied by an improve- 
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Proposed schema for the potential pathways involving myocardial fibrosis in the development of left ventricular dysfunction and heart failure associated with hypertensive heart disease. ment in diastolic function in patients with HHD, and these changes were independent of LVH regression. It has been reported that an inverse association exists between CVF and left ventricular chamber stiffness in patient with HHD [31] . Furthermore, the ability of losartan to reduce fibrosis was associated with reduction of myocardial stiffness in these patients [31] . An association was noted between severe ventricular fibrosis and deterioration of the ejection fraction in patients with HHD [32, 33] . Finally, CVF was reported to be higher in hypertensive patients with systolic heart failure than in those with diastolic heart failure [34] .
Myocardial Fibrosis and Other Cardiac Complications
Perivascular fibrosis may contribute to reduced coronary flow reserve associated with HHD. Schwartzkoppf et al. [35] demonstrated that perivascular CVF correlated inversely with coronary flow reserve in hypertensive people. The same group showed that treatment with perindopril induced an improvement in coronary flow reserve in hypertensive patients that was associated with significant regression in periarteriolar fibrosis and slight, but not significant, reduction in media hypertrophy [22] . The importance of periarteriolar collagen for coronary flow reserve was further elucidated by Isoyama et al. [36] . The normalization of blood pressure after debanding of the rat aorta induced regression of media hypertrophy, but the normalization of coronary flow reserve was achieved only after the additional reversal of collagen accumulation in the adventitia with -aminopropionitrile.
McLenachan and Dargie [32] found that patients with HHD and arrhythmias exhibited higher values of left ventricular mass and CVF than patients without arrhythmias. Ejection fraction and the frequency of coronary vessels with significant stenosis were similar in the two groups of patients. Bethge et al. [37] reported an association between fibrosis and arrhythmias in patients with HHD but without coronary artery disease or heart failure. Thus, the development of ventricular arrhythmias in patients with HHD may be related to fibrosis. The possibility also exists that atrial fibrosis is involved in increased occurrence of atrial fibrillation reported in patients with HHD [38] . Fibrosis is thought to disturb anisotropic conduction and thereby induce slowing of electrical conduction velocities, allowing for the generation of re-entry circuits [39] . In addition, impaired anisotropic conduction leads to chaotic rather than linear electrical propagation which also promotes arrhythmia [40] .
CLINICAL HANDLING OF MYOCARDIAL FIBRO-SIS IN HHD
From the above considerations, it can be assumed that to assess and reduce the extent of collagen accumulation in the left ventricle may be relevant in both improving the diagnosis of HHD and optimizing the prevention of heart failure and adverse cardiovascular events in patients with this condition.
Non-Invasive Assessment
Although microscopic examination of cardiac biopsies is the most reliable method for documenting and measuring myocardial fibrosis, this is an invasive methodology not useful for wide-scale application, and that may be subject to sampling error. Thus, the development of non-invasive methods to indicate the presence of left ventricular fibrosis in hypertensive patients would have a broader application.
The interaction of ultrasound waves with normal myocardial tissue results in reflected ultrasonic signals that exhibit characteristics different from those obtained when ultrasound interacts with abnormal tissue (i.e., fibrotic tissue) [41] . These characteristics are amenable to quantitation (one of the approaches being the measurement of tissue-integrated backscatter), that define the myocardial structure and functional attributes. In this regard, an association between alterations in echoreflectivity, namely diminution in the cyclic variation of backscatter signal, and increase in fibrous tissue was shown in the heart of hypertensive patients [42, 43] . Recently, it has been reported that alterations in the composition of the myocardium detected with magnetic resonance imaging using the contrast agent gadolinium had a strong correlation with histologically assessed myocardial fibrosis in patients with arrhythmogenic right ventricular displasia [44] . Therefore, image texture analysis appears to be a fertile area for research of non-invasive assessment of myocardial fibrosis in HHD.
The measurement of serum concentrations of the carboxy-terminal propeptide of procollagen type I or PICP (a peptide that is cleaved from procollagen type I during the synthesis of fibril-forming collagen type I) has been shown to be associated with CVF in both SHR [45] and patients with HHD [24] . In addition, changes induced by the antihypertensive treatment in serum PICP have been shown to be associated with changes in CVF in these patients [31, 46] . Recently, we found that the concentration of PICP was significantly higher in coronary sinus blood than in peripheral vein blood in patients with HHD, but not in normotensive subjects [33] . In addition, PICP measured in peripheral blood was found to be associated with PICP measured in coronary blood and with the amount of collagen type I fibers present in the myocardium (Fig. 3) [33] . Albeit preliminary, these findings suggest the following: 1) circulating PICP detected in patients with HHD is essentially of cardiac origin, 2) serum PICP is a reliable index of the extent of collagen type Idependent fibrosis in the hypertensive myocardium, and 3)serum PICP is a useful marker to assess the ability of antihypertensive treatment to diminish collagen type I synthesis and reduce myocardial fibrosis in hypertensive patients.
Antifibrotic Strategies
The European Society of Hypertension and the European Society of Cardiology say, in their guidelines for the management of arterial hypertension, that "…future studies should investigate treatment-induced effects on indices of collagen content or fibrosis of the left ventricular wall, rather than on its mass only…" [47] . In this context, the findings of several studies raise the possibility of some antihypertensive drugs being useful in the reduction of myocardial fibrosis associated with HHD ( Table 1 ). In fact, several studies in patients with HHD have shown that drugs interfering with the production (i.e., ACE inhibitors) and actions (AT 1 receptor antagonists) of angiotensin II reduced myocardial fibrosis, independently from blood pressure control and LVH regression, and that this was associated with improved left ventricular diastolic function and coronary flow reserve [22, 23, 31, 46] . These data support experimental studies in spontaneously hypertensive rats (SHR) where the ACE inhibitor lisinopril [48] and the AT 1 receptor antagonist losartan [49, 50] have proved to be effective on reversing cardiac fibrosis beyond the antihypertensive efficacy. On the other hand, recent studies show that chronic administration of spironolactone is associated with a reduction in the circulating levels of PCIP and other biomarkers of collagen turnover in patients with cardiac diseases that evolve with myocardial fibrosis [51, 52] , suggesting that aldosterone may contribute to this lesion in cardiac patients. Recent experimental work has been conducted to examine alternative potential therapeutic strategies. For instance, it has been shown that statins prevent cardiac fibrosis that develops in hypertensive rats [53] [54] [55] . Preliminary data suggest that the antifibrotic effect of statins can be the result of a direct action on signals that cause fibroblast growth and activation [56] . It has been reported that some compounds reduce myocardial fibrosis in rats with experimental hypertension through mechanisms probably related to inhibition of TGF-synthesis and/or receptor binding [57, 58] . It has been described that PPAR-agonists reduce fibrosis in the heart of rats with pressure overload [59] [60] [61] [62] . Finally, the inhibition of the ubiquitin-proteasome system has been found to suppress fibrillar collagen expression in isolated fibroblasts and to reduce myocardial fibrosis in SHR [63] .
FUTURE PERSPECTIVES
A working hypothesis regarding genes that contribute to development of hypertension-related target-organ disease and its response to therapy is emerging [64, 65] . In this regard, global analysis of gene expression can be a fruitful means of examining the overall molecular portrait of the hypertensive myocardium as well as seeking out novel candidate transcripts that may play a role in fibrosis. On the other hand, knowledge of polymorphic variation in genes that encode for proteins that potentially regulate fibrogenic mechanisms may help in our understanding of how fibrosis develops in the hypertensive heart. In addition, knowledge of polymorphisms in genes that potentially influence pharmacodynamic mechanisms would allow the identification of individuals who are likely to have beneficial anti-fibrotic responses to treatment with a particular drug. Some examples may illustrate the potential usefulness of these genebased approaches.
First, in order to study, at the transcriptome level, the changes associated with the transition from LVH to heart failure, we performed recently a gene expression analysis of over 14,000 full-length genes (UniGene Clusters) using a high-density oligonucleotide array in endomyocardial samples from the interventricular septum of patients with HHD [66] . 191 genes -86 upregulated and 105 downregulatedshowed differential ( or 1.5-fold, respectively) expression in patients with LVH and heart failure compared with both patients with LVH and normal cardiac function and patients with no HHD. A number of genes encoding extracellular matrix components were overexpressed in the failing hypertensive heart. In fact, we observed an increased expression in genes encoding some major components of extracellular matrix (i.e., alpha 1 chain of collagen type I and fibronectin 1) in heart failure patients compared with LVH patients. In addition, the parallel overexpression of some molecules involved in the transduction of profibrotic signals, such as the TGF-receptor III and the connective tissue growth factor (CTGF), could contribute to the increase in myocardial fibrosis reported in patients with HHD and heart failure. In support of this possibility, it has been demonstrated that TGF-is a specific inducer of CTGF expression in both cardiac fibroblasts and cardiomyocytes and that the upregulation of CTGF was associated with an increase in fibronectin and collagen type I deposition [67] . Interestingly, among the few genes that were repressed in this category we found two genes related to collagen matrix disruption (cisteine rich, angiogenic inducer 61 or CYR61 and membrane-type-1 matrix metalloproteinase cytoplasmic tail binding protein-1 or MT-1-MMPCBP-1). It has been observed that CYR61 enhances the expression of matrix metalloproteinases 1 and 3, as well as the tissue inhibitor of matrix metalloproteinase (TIMP)-1 in skin fibroblasts [68] . Moreover, MT-1-MMPCBP-1 could be an inhibitor of proteolysis, as it has been shown in tumoral cells via inhibition of MT-1-MMP and MMP-14 [69] .
Second, Ocaranza et al. [70] reported recently that the B allele of the L/B polymorphism of the ACE gene determines a higher myocardial deposition of collagen type I fibers in rats submitted to isoproterenol infusion than does the L allele. Interestingly, homozygous BB rats exhibited higher left ventricle and plasma ACE activity than homozygous AA and heterozygous AB rats after isoproterenol infusion, suggesting that the polymorphism determines the responsiveness of the enzyme to ß-adrenergic stimulation. The potential pathophysiological relevance of this possibility is given by the observation that a direct correlation existed between left ventricle ACE activity and CVF in BB rats. Recently, it has been reported that an association exists between the I/D polymorphism of the ACE gene and serum PICP in hypertensive patients [71] . In fact, compared with patients with II or ID genotypes, patients with DD genotype showed higher serum PICP concentration and plasma ACE activity. Collectively, these observation support a role for gene variations influencing ACE activity on myocardial fibrosis.
Finally, we have examinated the potential role of the A1166C polymorphism of the AT 1 receptor gene on the response of collagen type I metabolism to antihypertensive treatment [72] . In the study, patients with HHD were studied before and after 1 year after treatment with losartan or atenolol. Baseline PICP was significantly increased in AA hypertensives compared with AC/CC hypertensives. Confounding factors were similar in the two subgroups of hypertensives. Administration of the AT 1 receptor antagonist losartan was associated with significant reduction in PICP in AA hypertensives but not AC/CC hypertensives. Treatment with atenolol did not change PICP in either subgroup of hypertensives. Blood pressure was reduced to the same extent in the four treatment subgroups. If these results were confirmed by larger, prospective, double-blind studies, the genotype of the A1166C polymorphism of the AT 1 receptor gene could be a useful indicator for antihypertensive drug strategy aimed to reduce myocardial fibrosis in patients with HHD.
CONCLUSIONS
HHD arises not only as the result of the hypertrophy of cardiomyocytes but also because of alterations in the noncardiomyocyte compartment of the myocardium (i.e., alterations in the collagen network leading to an exaggerate deposition of collagen fibers or fibrosis). The available data indicate that besides mechanical stress, a variety of humoral factors, namely angiotensin II, might contribute to ventricular fibrosis in patients with HHD. In turn, fibrosis could facilitate the development of cardiac complications, including heart failure, in these patients. Therefore, management of patients with HHD must focus on more than the diagnosis and correction of hypertension and LVH. A better approach is to incorporate interventions aimed at detecting and targeting ventricular fibrosis. There is promising evidence that the measurement of serum PICP and quantitative analysis of echoreflectivity reflects the presence of fibrosis in the myocardium of hypertensive patients. In addition, preliminary data suggest that the goal of reducing ventricular fibrosis is achievable in patients with HHD by use of antihypertensive agents that reduce the production and actions of angiotensin II. Large and long-term clinical trials are necessary to determine whether such an approach is definitively associated with beneficial effects on the patient's cardiac function and prognosis.
